Brazilian experience in EU-CORE: daptomycin registry and treatment of serious Gram-positive infections

Timerman, Artur; Brites, Carlos; Bicudo, Eliana; Grinbaum, Renato Satovschi; Filho, Rubens Costa; Carrilho, Claudia D.M.; Bichels, Andre; Barreto, Tânia

doi:10.1016/j.bjid.2013.03.005

Cited by 4 publications

(2 citation statements)

References 27 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rege et al have reported good tolerability and high clinical success rates with daptomycin when administered for >14 days, in a patient population from the USA [ 34 ]. Similarly, the results from an 8-year clinical experience with daptomycin showed favorable safety and effectiveness profiles with lower overall clinical failure rates in Europe, Latin America, and Asia [ 33 , 40 , 43 ]. These results complement the previously published data from randomized clinical trials [ 31 , 32 ].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, patients with LIE, osteomyelitis, prosthetic joint infections, neutropenic fever, sepsis of unknown origin, and surgical site infections caused by Gram-positive pathogens were also treated, which reflects an unmet medical need of approved treatment options for these conditions. Several reports have suggested that daptomycin is effective and has an overall good safety profile in various clinical conditions such as SSTI, bacteremia, osteomyelitis and endocarditis in different geographical regions [ 15 , 29 , 41 – 43 ]. Rege et al have reported good tolerability and high clinical success rates with daptomycin when administered for >14 days, in a patient population from the USA [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE

Seaton

Gonzalez-Ruiz

Cleveland

et al. 2016

Ann Clin Microbiol Antimicrob

View full text Add to dashboard Cite

BackgroundPooled data from two large registries, Cubicin® Outcomes Registry and Experience (CORE; USA) and European Cubicin® Outcomes Registry and Experience (EU-CORE; Europe, Latin America, and Asia), were analyzed to determine the characteristics and clinical outcomes of daptomycin therapy in patients with Gram-positive infections across wide geographical regions.MethodsPatients receiving at least one dose of daptomycin between 2004 and 2012 for the treatment of Gram-positive infections were included. Clinical success was defined as an outcome of ‘cured’ or ‘improved’. Post-treatment follow-up data were collected for a subset of patients (CORE: osteomyelitis and orthopedic foreign body device infection; EU-CORE: endocarditis, intracardiac/intravascular device infection, osteomyelitis, and orthopedic device infection). Safety was assessed for up to 30 days after daptomycin treatment.ResultsIn 11,557 patients (CORE, 5482; EU-CORE, 6075) treated with daptomycin (median age, 62 [range, 1–103] years), the most frequent underlying conditions were cardiovascular disease (54.7 %) and diabetes mellitus (28.0 %). The most commonly treated primary infections were complicated skin and soft tissue infection (cSSTI; 31.2 %) and bacteremia (21.8 %). The overall clinical success rate was 77.2 % (uncomplicated SSTI, 88.3 %; cSSTI, 81.0 %; osteomyelitis, 77.7 %; foreign body/prosthetic infection (FBPI), 75.9 %; endocarditis, 75.4 %; and bacteremia, 69.5 %). The clinical success rate was 79.1 % in patients with Staphylococcus aureus infections (MRSA, 78.1 %). An increasing trend of high-dose daptomycin (>6 mg/kg/day) prescribing pattern was observed over time. Clinical success rates were higher with high-dose daptomycin treatment for endocarditis and FBPI. Adverse events (AEs) and serious AEs possibly related to daptomycin therapy were reported in 628 (5.4 %) and 133 (1.2 %) patients, respectively.ConclusionsThe real-world data showed that daptomycin was effective and safe in the treatment of various Gram-positive infections, including those caused by resistant pathogens, across wide geographical regions.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE

Seaton

Gonzalez-Ruiz

Cleveland

et al. 2016

Ann Clin Microbiol Antimicrob

View full text Add to dashboard Cite

show abstract

A comparison of different antibiotic regimens for the treatment of infective endocarditis

Martí‐Carvajal¹,

Dayer

Conterno

et al. 2016

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundInfective endocarditis is a microbial infection of the endocardial surface of the heart. Antibiotics are the cornerstone of treatment, but due to the di erences in presentation, populations a ected, and the wide variety of micro-organisms that can be responsible, their use is not standardised. This is an update of a review previously published in 2016. ObjectivesTo assess the existing evidence about the clinical benefits and harms of di erent antibiotics regimens used to treat people with infective endocarditis. Search methodsWe searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase Classic and Embase, LILACS, CINAHL, and the Conference Proceedings Citation Index -Science on 6 January 2020. We also searched three trials registers and handsearched the reference lists of included papers. We applied no language restrictions. Selection criteriaWe included randomised controlled trials (RCTs) assessing the e ects of antibiotic regimens for treating definitive infective endocarditis diagnosed according to modified Duke's criteria. We considered all-cause mortality, cure rates, and adverse events as the primary outcomes. We excluded people with possible infective endocarditis and pregnant women. Data collection and analysisTwo review authors independently performed study selection, 'Risk of bias' assessment, and data extraction in duplicate. We constructed 'Summary of findings' tables and used GRADE methodology to assess the quality of the evidence. We described the included studies narratively.A comparison of di erent antibiotic regimens for the treatment of infective endocarditis (Review)

show abstract

The History of Methicillin-Resistant Staphylococcus aureus in Brazil

Andrade

Luiz

Souza

et al. 2020

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

Since the emergence of MRSA in the 1960s, a gradual increase in infections by resistant bacteria has been observed. Clinical manifestations may vary from brand to critical condition due to host risk factors, as well as pathogen virulence and resistance. The high adaptability and pathogenic profile of MRSA clones contributed to its spread in hospital and community settings. In Brazil, the first MRSA isolates were reported in the late 1980s, and since then different genetic profiles, such as the Brazilian epidemic clone (BEC) and other clones considered a pandemic, became endemic in the Brazilian population. Additionally, Brazil’s MRSA clones were shown to be able to transfer genes involved in multidrug resistance and enhanced pathogenic properties. These events contributed to the rise of highly resistant and pathogenic MRSA. In this review, we present the main events which compose the history of MRSA in Brazil, including numbers and locations of isolation, as well as types of staphylococcal cassette chromosome mec (SCCmec) found in the Brazilian territory.

show abstract

Brazilian experience in EU-CORE: daptomycin registry and treatment of serious Gram-positive infections

Abstract: Daptomycin had a relevant role in the treatment of Gram-positive infections in the clinical practice setting in Brazil.

Cited by 4 publications

References 27 publications

Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE

Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE

A comparison of different antibiotic regimens for the treatment of infective endocarditis

The History of Methicillin-Resistant Staphylococcus aureus in Brazil

Contact Info

Product

Resources

About